French biotech startup Generare has closed a €5 million seed round (around $5.5 million at current exchange rates) to step up development of what it touts as a highly scalable approach to identifying promising compounds for drug discovery that already exist in nature. It’s focused on sifting for mo...
Read Also
- How to Spot a Bad Prime Day Deal
- Research suggests Earth's oldest continental crust is disintegrating
- Tunisian snail remains provide insights on a possible 7700-year-old local food tradition
- Sperm whale departure linked to decline in jumbo squid population in Gulf of California
- Relive the best the ’80s had to offer with Universal’s 10-Film 1980s Collection
- Lithios takes inspiration from battery manufacturing to mine lithium from salty water
- SpaceX launches Hera asteroid mission, but delays Europa Clipper because of Hurricane Milton
- Best Prime Day Apple deals to shop in October 2024
- The Tineco Floor One S5, a True Game-Changer For Cleaning, is Offered At a 42% Discount on Amazon
- Detecting Planck-scale dark matter by leveraging quantum interference
Latest TechCrunch
- Lithios takes inspiration from battery manufacturing to mine lithium from salty water
- Uber to launch OpenAI-powered AI assistant to answer driver EV questions
- Open source BI platform Lightdash gets Accel’s backing to bring AI to business intelligence
- Revyze, a ‘TikTok for education’ startup, draws on Duolingo to add bite-sized learning too
- French biotech Generare speeds up hunt for new drugs by cloning natural molecules
- Chainalysis CEO Michael Gronager steps down in move described as temporary
- General Catalyst is working on a ‘continuation’ fund worth up to $1B, sources say
- VC firm NFX laid off 4 employees and plans to hire more investors
- VESSL AI secures $12M for its MLOps platform that aims to cut GPU costs by up to 80%
- VESSL AI secures $12M for its MLOps platform that aims to cut GPU costs by up to 80%